ERBB2 and neoplasm: For internalizing tumor-associated targets like HER2, the use of residualizing prosthetic agents for sdAb radioiodination has shown great potential and in some respects—notably, lower trapping of radioactivity in the kidneys—can offer substantive advantages compared with their radiometal-labeled counterparts19,20.